CorMedix, Inc. (CRMD) Notes Latest FDA Correspondence regarding Neutrolin®

QualityStocks would like to highlight CorMedix Inc. (NYSE AMEX: CRMD), a pharmaceutical company that seeks to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart.

In the company’s news yesterday,

CorMedix detailed its latest correspondence from the U.S. Food and Drug Administration (FDA) regarding the company’s regulatory submission for Neutrolin®.

Neutrolin is the CorMedix’s candidate for the prevention of catheter-related bloodstream infections. The company recently filed a Request for Designation (RFD), which allows the FDA to determine the product type and assign the product to the appropriate lead center.

In its filing, CorMedix proposed for Neutrolin to be classified as a device and assigned to the Center For Devices and Radiological Health as lead reviewer. The company noted that the RFD filing is the company’s response to communication from the FDA following CorMedix’s Investigational Device Exemption (IDE) amendment submission.

If the FDA hasn’t responded with a designation letter within 60 calendar days of the filing of the RFD, CorMedix’s recommendation will stand as the designated classification and assignment.

CorMedix expects to launch its clinical study of Neutrolin in the second half of 2011, contingent on the pending device designation and IDE approval.

CorMedix also said it expects to complete the initial submission of the Neutrolin Design Dossier to the European notified body by the end of the second quarter 2011.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.